GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Effect of Exchange Rate Changes

Biogen (BSP:BIIB34) Effect of Exchange Rate Changes : R$-42 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Biogen Effect of Exchange Rate Changes?

Biogen's Effect of Exchange Rate Changes for the three months ended in Mar. 2024 was R$-115 Mil.

Biogen's Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2024 was R$-42 Mil.

Biogen Effect of Exchange Rate Changes Historical Data

The historical data trend for Biogen's Effect of Exchange Rate Changes can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Effect of Exchange Rate Changes Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effect of Exchange Rate Changes
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.64 354.98 -338.16 -292.17 171.98

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effect of Exchange Rate Changes Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.17 -19.90 -141.74 234.70 -115.03

Biogen Effect of Exchange Rate Changes Calculation

Effect of Exchange Rate Changes represents the effect of exchange rate changes on cash balances held in foreign currencies.

Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Effect of Exchange Rate Changes Related Terms

Thank you for viewing the detailed overview of Biogen's Effect of Exchange Rate Changes provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Effect of Exchange Rate Changes
Comparable Companies
OGN AMRN SCLX MIRA GILD BMY AMGN LLY JNJ MRK ABBV LSE:AZN XSWX:ROG XSWX:NOVN PFE XPAR:SAN LSE:GSK TSE:4519 TSE:4568 SHSE:600276
Traded in Other Exchanges
BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB:Austria BIIB:Argentina
Address
225 Binney Street, Cambridge, MA, USA, 02142
Website
https://www.biogen.com
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines